All News

2020

January

Media Release / Jan 20, 2020

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

Read More
2019

September

Media Release / Sep 13, 2019

Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

Read More
Media Release / Sep 13, 2019

New Novartis data show that neuronal and glial filaments, biomarkers of disease activity, have the potential to support decision making in the management of multiple sclerosis (MS) patient

Read More
Media Release / Sep 10, 2019

Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)

Read More
Media Release / Sep 09, 2019

Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More